Simulations Plus Inc SLP:NASDAQ

Earnings Announcement Next Earnings date is expected on 07/06/2022
Last Price$48.09NASDAQ Previous Close - Last Trade as of 4:00PM ET 6/28/22

Today's Change-0.40(0.82%)
Bid (Size)$38.10 (1)
Ask (Size)$57.77 (10)
Day Low / High$47.68 - 48.84
Volume101.4 K
 

View Packaged Software IndustryPeer Comparison as of 06/28/2022

 

Simulations Plus Inc ( NASDAQ )

Price: $48.09
Change: -0.40 (0.82%)
Volume: 101.4 K
4:00PM ET 6/28/2022
 
 

Donnelley Financial Solutions Inc ( NYSE )

Price: $29.20
Change: -0.83 (2.76%)
Volume: 222.1 K
7:00PM ET 6/28/2022
 
 

SecureWorks Corp ( NASDAQ )

Price: $11.00
Change: -0.19 (1.70%)
Volume: 73.7 K
4:00PM ET 6/28/2022
 
 

Domo Inc ( NASDAQ )

Price: $30.02
Change: -0.95 (3.07%)
Volume: 349.9 K
4:00PM ET 6/28/2022
 
 

Health Catalyst Inc ( NASDAQ )

Price: $15.40
Change: -1.15 (6.95%)
Volume: 1.3 M
4:00PM ET 6/28/2022
 

Read more news Recent News

Insider Sell: Simulations Plus
2:51PM ET 6/01/2022 MT Newswires

Walter S Woltosz, 10% Owner, Director, on May 27, 2022, sold 20,000 shares in Simulations Plus (SLP) for $959,727. Following the Form 4 filing with the...

US FDA Renews Simulations Plus' DILIsym Software Licenses for 2022
1:44PM ET 5/05/2022 MT Newswires

Simulations Plus (SLP) said Thursday the US Food and Drug Administration renewed its annual licenses to the DILIsym software platform. The platform is the...

Insider Sell: Simulations Plus
12:06PM ET 4/29/2022 MT Newswires

Walter S Woltosz, 10% Owner, Director, on April 27, 2022, sold 20,000 shares in Simulations Plus (SLP) for $937,716. Following the Form 4 filing with the...

Simulations Plus Offers Promising Growth Prospects, Oppenheimer Says
1:18PM ET 4/07/2022 MT Newswires

Simulations Plus (SLP) offers good growth prospects amid improved backlog and increased bookings, Oppenheimer said after the company reported strong fiscal...

Company Profile

Business DescriptionSimulations Plus, Inc. provides modeling and simulation software and consulting services supporting drug discovery, development research and regulatory submissions. The firm operates through the following segments: Simulations Plus, Cognigen, DILIsym and Lixoft. It designs and develops pharmaceutical simulation software to promote cost-effective solutions to a number of problems in pharmaceutical research and in the education of pharmacy and medical students. The company was founded by Walter S. Woltosz and Virginia E. Woltosz on July 17, 1996 and is headquartered in Lancaster, CA. View company web site for more details
Address42505 10th Street West
Lancaster, California 93534-7059
Phone+1.661.723.7723
Number of Employees95
Recent SEC Filing06/01/20224
Chief Executive OfficerShawn M. O'Connor
Chief Financial Officer & SecretaryWilliam W. Frederick
President-Lancaster DivisionJohn Anthony DiBella
Director-MarketingArlene Padron

Company Highlights

Price Open$48.84
Previous Close$48.09
52 Week Range$35.18 - 57.96
Market Capitalization$971.7 M
Shares Outstanding20.2 M
SectorTechnology Services
IndustryPackaged Software
Current Dividend / Yield$0.06 / 0.49%
Dividend Ex-Date04/22/2022
Dividend Pay-Date05/02/2022
Dividend Yield 5 Year AverageN/A
Next Earnings Announcement07/06/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings90.49
Earnings per Share$0.57
Beta vs. S&P 500N/A
Revenue$29.7 M
Net Profit Margin23.13%
Return on Equity6.86%

Analyst Ratings as of 04/17/2022

Buy
2
Overweight
1
Hold
1
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset